Legal & General Group Plc Makes New $3.25 Million Investment in DENTSPLY SIRONA Inc. $XRAY

Legal & General Group Plc acquired a new stake in DENTSPLY SIRONA Inc. (NASDAQ:XRAY) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 306,265 shares of the medical instruments supplier’s stock, valued at approximately $3,249,000. Legal & General Group Plc owned 0.15% of DENTSPLY SIRONA at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in DENTSPLY SIRONA during the first quarter worth about $26,000. Goldman Sachs Group Inc. boosted its stake in shares of DENTSPLY SIRONA by 827.3% in the first quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock valued at $36,378,000 after purchasing an additional 2,172,343 shares during the period. Empowered Funds LLC boosted its stake in shares of DENTSPLY SIRONA by 8.8% in the first quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 1,320 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock valued at $8,860,000 after purchasing an additional 41,579 shares in the last quarter. Finally, Focus Partners Wealth grew its holdings in shares of DENTSPLY SIRONA by 59.1% in the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock valued at $376,000 after purchasing an additional 9,355 shares in the last quarter. Institutional investors and hedge funds own 95.70% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on XRAY shares. BMO Capital Markets reiterated a “market perform” rating and set a $13.00 target price on shares of DENTSPLY SIRONA in a report on Friday, August 7th. Piper Sandler increased their price objective on DENTSPLY SIRONA from $13.00 to $14.00 and gave the company a “neutral” rating in a research note on Wednesday, July 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of DENTSPLY SIRONA in a report on Monday, August 3rd. Barclays boosted their target price on DENTSPLY SIRONA from $9.00 to $11.00 and gave the stock an “underweight” rating in a research note on Monday, August 24th. Finally, Barrington Research set a $15.00 target price on shares of DENTSPLY SIRONA in a research note on Monday, August 10th. Three equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $13.54.

DENTSPLY SIRONA Stock Performance

Shares of XRAY opened at $11.38 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.07 and a debt-to-equity ratio of 1.48. The firm has a market cap of $2.27 billion, a PE ratio of -4.14, a price-to-earnings-growth ratio of 1.45 and a beta of 0.84. The company’s 50 day simple moving average is $12.16 and its 200-day simple moving average is $11.67. DENTSPLY SIRONA Inc. has a 12-month low of $9.40 and a 12-month high of $14.86.

DENTSPLY SIRONA (NASDAQ:XRAY) last released its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $0.52 EPS for the quarter, beating the consensus estimate of $0.35 by $0.17. DENTSPLY SIRONA had a negative net margin of 14.99% and a positive return on equity of 20.84%. The firm had revenue of $898.00 million during the quarter, compared to the consensus estimate of $889.93 million. During the same quarter in the prior year, the firm earned $0.52 EPS. DENTSPLY SIRONA’s revenue for the quarter was down 4.1% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. As a group, equities analysts predict that DENTSPLY SIRONA Inc. will post 1.4 EPS for the current year.

Insider Activity at DENTSPLY SIRONA

In related news, Director Brian T. Gladden purchased 9,985 shares of the business’s stock in a transaction dated Monday, June 15th. The stock was acquired at an average price of $10.02 per share, for a total transaction of $100,049.70. Following the acquisition, the director directly owned 61,849 shares of the company’s stock, valued at $619,726.98. This trade represents a 19.25% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brian P. Mckeon acquired 10,000 shares of the firm’s stock in a transaction that occurred on Friday, June 12th. The shares were bought at an average cost of $10.12 per share, for a total transaction of $101,200.00. Following the acquisition, the director owned 10,000 shares of the company’s stock, valued at $101,200. This represents a ∞ increase in their position. The SEC filing for this purchase provides additional information. Insiders have acquired a total of 35,160 shares of company stock worth $351,179 over the last three months. 0.46% of the stock is currently owned by corporate insiders.

DENTSPLY SIRONA Profile

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.